MétaCan
Menu
Back to cohort

Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus

2025· letter· en· W4408186546 on OpenAlexaff
Elisabeth J. Cohen, Andrea B. Troxel, Mengling Liu, Judith S. Hochman, Keith H. Baratz, Shahzad I. Mian, Mazen Y. Choulakian, David B. Warner, Ying Lu, Alberta Twi-Yeboah, Ting‐Fang Lee, Jiyu Kim, Carlos Lopez-Jimenez, Sarah Laury, Bennie H. Jeng, Sarah B. Weissbart, Azin Abazari, Timothy Chou, Eileen Chang, Guillermo Amescua, Rahul Tonk, Ellen Koo, Jaime D. Martinez, Anat Galor, Sanjay V. Patel, John S. Berestka, Afshan Nanji, Winston Chamberlain, Richard D. Stutzman, John Clements, James Chodosh, Emma Davies, Hajirah N. Saeed, Jessica Ciralsky, A. Gómez-Bastero Fernández, Kimberly C. Sippel, Victor L Perez-Quinones, Melissa B. Daluvoy, Katy C. Liu, M. Ewald, Erich B Groos, Bernard Chang, Ira A. Shivitz, Jordan Hill, Priscilla G. Fowler, Russell W. Read, Harry S. Geggel, Ahmed F. Omar, Christopher J. Rapuano, Beeran Meghpara, Zeba A. Syed, Gary N. Holland, Olivia Lee, John Irvine, Sophie X. Deng, Anthony J. Aldave, Tsui Edmund, Judy Chen, Marc A Honig, Andrew Huang, Todd P. Margolis, Anthony J. Lubniewski, Douglas Katz, Seema Capoor, John Gonzales, Gerami D. Seitzman, Jeremy Keenan, Melina I. Morkin, Kenneth R. Kenyon, Pedram Hamrah, William B. Lee, Joseph Christenbury, Kara C. LaMattina, Hyunjoo Lee, Kambiz Negahban, Christine S Ament, Marta O. Lopatynsky, John D Barbato, Jayati S Sarkar, Marian S. Macsai, Joshua B Herz, Mitchell P. Weikert, Zaina Al-Mohtaseb, Alice Y. Matoba, Theresa Cooney, Christopher T. Hood, Maria A. Woodward, Alan Sugar, Roni M. Shtein, Sarah Nehls, Evan J. Warner, Greg Nettune, Henry Gelender, Jamie K. Alexander, Tyrone McCall, Joshua Zaffos, Walter E. Beebe, Luke B. Potts, Jay M. Lustbader, Aruoriwo Oboh-Weilke, K.M. Hammersmith, Stephen E. Orlin, Parveen K. Nagra, Michael E. Sulewski, Vatinee Y. Bunya, Brian M. Shafer, Christina R. Prescott, Ilyse Haberman, Elizabeth T. Viriya, Anam Qureshi, Douglas R. Lazzaro, Laura Palazzolo, Himani Goyal, Katie E Schrack, Irving M. Raber, Brandon D. Ayres, Brenton Finklea, Sherman W. Reeves, David R. Hardten, Charles Reilly, William J. Flynn, Angie E Wen, David C. Ritterband, David J. Harris, Sumayya Ahmad, Neha Shaik, John A. Seedor, Steven I. Rosenfeld, Marc Winnick, Ahmad Fitri Amir, Mark D. Sherman, Divya Srikumaran, Esen K. Akpek, Benjamin Chaon, Sarkis H. Soukiasian, Naveen K. Rao, Anne Steiner, Jules Winokur, Ira J. Udell, Carolyn Shih, Matthew Gorski, Amilia Schrier, Ann-Marie Lobo-Chan, Joel Sugar, Elmer Y. Tu, Sarah B. Sunshine, Donald M. Miller, William G. Gensheimer, Michael E. Zegans, Jayne S. Weiss, María José Bernal, Bruce J. Barron, Holly B. Hindman, R. Wise, Christopher D. Gelston, Michael J. Taravella, Richard S. Davidson, Uyen Tran, Christine Shieh, Jeremy Bartley, James P. McCulley, Steven M. Verity, Wayne Bowman, Preston H. Blomquist, V. Vinod Mootha, George Thorne, Ann M Renucci, David D. Verdier, K. R. Sivaraman, Michael L. Nordlund, Frank S. Hwang, John E. Affeldt, Herbert J. Ingraham, Nathalie M. Guibord, Kendall Dobbins, Tarika Thareja, Amy Lin, Brian Zaugg, Mark D. Mifflin, S. LANCE FORSTOT, Karen Repine, Michael Wildes, Christopher B. Estopinal, Donna Brown, Aaleya Koreishi, Patricia Ple-plakon, Carol S. Clemons, Ravi B. Patel, Penny A. Asbell, S Ashe, Sarah G. Bonaffini, Kourtney Houser, M. Christopher Wallace, Jesse M Wesberry, Alfonso Iovieno, Sonia N. Yeung, Joshua C. Teichman, Nima Noordeh, Anne Faucher, Marie‐Claude Robert, Mona Harissi‐Dagher, Jacob Rullo, Stephanie Baxter, Davin Johnson, Dean Mah, Matthew D. Benson, Stephan Ong Tone, Hall F. Chew, Mojgan Hassonlou, Shaohui Liu, Jennifer Eikenberry, Chi-Wah Yung, Joanne F Shen, Charles C. Lin, Charles Yu, Christopher N. Ta, Kenneth M. Goins, John E. Sutphin, Kerri Svanda, Stacy Keppol, Audrey Talley Rostov, Neil Vyas, Kimberly Hsu, Gerri Goodman, Lisa McHam, Ramy Rizkalla, Anita N. Shukla, Mathew Veena, Craig W. See, Jeffrey M. Goshe, Robert S. Feder, Jeanine Baqai, Surendra Basti, Ramez I. Haddadin, Jae Young You, Lena Dixit, Ravi H Patel, Kimberly T Golde, Gerald W. Zaidman, Sankara Mahesh, Vikas Sharma, Jason D. Wesolosky, Darby D. Miller, Helen Jeffrey, Mark J. Mannis, Jay J. Meyer, Rachael L. Niederer, Kathryn Colby, Stephen D. McLeod, Michele Melia, Elizabeth A. Sugar, Carol R. Taylor, Maria A. Nagel, William J. Dupps, Jonathan H. Lass

Bibliographic record

VenueJAMA Ophthalmology · 2025
Typeletter
Languageen
FieldMedicine
TopicHerpesvirus Infections and Treatments
Canadian institutionsUniversité de Sherbrooke
Fundersnot available
KeywordsMedicineHerpes Zoster OphthalmicusDermatologyValaciclovirOptometryOphthalmologyVirologyHerpesviridaeViral diseaseHuman immunodeficiency virus (HIV)

Abstract

fetched live from OpenAlex

Importance: High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care. Objective: To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis, or dendriform epithelial keratitis (DEK) during 12 months of treatment and if treatment benefit persisted at 18 months (secondary end point). Design, Setting, and Participants: The Zoster Eye Disease Study (ZEDS) was a randomized clinical trial conducted in 95 sites from November 2017 to June 2024. Immunocompetent, nonpregnant adults with a history of an HZO rash, documented active keratitis or iritis within 1 year, and an estimated glomerular filtration rate of 45 mL/min/1.73 m2 or greater were eligible. After determined to be eligible, participants were randomized in 4 strata: age at onset (<60 years vs ≥60 years) and disease duration (<6 months vs ≥6 months). Interventions: A total of 12 months of double-masked daily valacyclovir, 1000 mg, or placebo. Main Outcomes and Measures: The primary outcome was time to first occurrence within 12 months of new or worsening SK, EK, iritis, or DEK. Results: A total of 527 participants (median [IQR] age, 60 [50-68] years; 266 female [50.5%]; 266 in the valacyclovir group; 261 in the placebo group) were randomized in 4 strata; 481 completed 12 months, and 460 completed 18 months. Data were analyzed by intention to treat. At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at 18 months in 104 participants (40%) assigned to placebo and 86 (32%) assigned to valacyclovir. The hazard ratio (HR) of the primary end point at 12 months was 0.77 for participants taking valacyclovir vs placebo (HR, 0.77; adjusted 95% CI, 0.56-1.05; P = .09) and 0.73 at the secondary end point at 18 months (HR, 0.73; adjusted 95% CI, 0.55-0.97; P = .03). There was a reduction of multiple other secondary end points at 12 months (HR, 0.70; 95% CI, 0.52-0.95; P = .02) and 18 months (HR, 0.72; 95% CI, 0.55-0.95; P = .02). Conclusions and Relevance: Although the primary outcome did not show a benefit of suppressive valacyclovir treatment, secondary study outcomes showed treatment superiority at the 18-month end point and reduced number of multiple episodes of keratitis or iritis at both 12 and 18 months. These results support consideration of 1 year of suppressive valacyclovir treatment for HZO. Trial Registration: ClinicalTrials.gov Identifier: NCT03134196.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Research integrity, Insufficient payload (model declined to judge)
Consensus categoriesResearch integrity, Insufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.203
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.313
Teacher spread0.291 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJAMA OphthalmologySame topicHerpesvirus Infections and TreatmentsFrench-language works237,207